Medicine · 2026
Exogenous insulin antibody syndrome presenting with concurrent hypoglycemia and hyperglycemia: A case report following complete pancreatectomy.
СтатьяКлинический случайНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Xiao-Po, Wu Yan, Wu Jing, Liu Ying-Zhao, Jiang Hui
Аннотация
RATIONALE: Antibodies against therapeutic insulin cause paradoxical hypoglycemia, termed exogenous insulin antibody syndrome (EIAS). This first report of glargine-induced EIAS post-total pancreatectomy introduces mycophenolate mofetil (MMF) as a novel steroid-sparing therapy.
PATIENT CONCERNS: A 75-year-old woman developed refractory nocturnal hypoglycemia with daytime hyperglycemia (HbA1c 8.6%) 3 months post-pancreatectomy during glargine therapy.
DIAGNOSES: Hypoglycemia (glucose 2.83 mmol/L) featured undetectable C-peptide, elevated insulin (103 μU/mL), high insulin autoantibodies (74.95 coi, Reference range 0-1.0), and polyethylene glycol (PEG) precipitation-confirmed antibody-bound insulin, with a marked decline in insulin concentration relative to baseline values (88% decline).
INTERVENTIONS: Standard approaches (switching to aspart insulin, carbohydrate enrichment, degludec/acarbose triple regimen) failed; prednisone alleviated hypoglycemia but provoked hyperglycemia.
OUTCOMES: Mycophenolate mofetil (MMF) eliminated hypoglycemia within 2 weeks, reducing antibodies to 35.4 coi.
CONCLUSION: This inaugural case highlights EIAS as a cause of unexplained hypoglycemia in pancreatectomized patients. MMF warrants consideration as primary immunosuppressive therapy for EIAS.
LESSONS: This case highlights that EIAS is a rare but important cause of paradoxical hypoglycemia and hyperglycemia in insulin-treated patients. MMF can serve as an effective therapeutic agent.
PATIENT CONCERNS: A 75-year-old woman developed refractory nocturnal hypoglycemia with daytime hyperglycemia (HbA1c 8.6%) 3 months post-pancreatectomy during glargine therapy.
DIAGNOSES: Hypoglycemia (glucose 2.83 mmol/L) featured undetectable C-peptide, elevated insulin (103 μU/mL), high insulin autoantibodies (74.95 coi, Reference range 0-1.0), and polyethylene glycol (PEG) precipitation-confirmed antibody-bound insulin, with a marked decline in insulin concentration relative to baseline values (88% decline).
INTERVENTIONS: Standard approaches (switching to aspart insulin, carbohydrate enrichment, degludec/acarbose triple regimen) failed; prednisone alleviated hypoglycemia but provoked hyperglycemia.
OUTCOMES: Mycophenolate mofetil (MMF) eliminated hypoglycemia within 2 weeks, reducing antibodies to 35.4 coi.
CONCLUSION: This inaugural case highlights EIAS as a cause of unexplained hypoglycemia in pancreatectomized patients. MMF warrants consideration as primary immunosuppressive therapy for EIAS.
LESSONS: This case highlights that EIAS is a rare but important cause of paradoxical hypoglycemia and hyperglycemia in insulin-treated patients. MMF can serve as an effective therapeutic agent.